TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects Inappropriately Shocked by ICD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of development of postoperative pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Endpoint of Total Ischemic Events, Thromboembolic Events, Pump Hemolysis or Thrombosis, Pump Exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative bioavailability of BMS-931699
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Nasal Symptom Score (TNSS) of nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to treatment discontinuation (TTD)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: episodes of urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in psoriatic infiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Elasticity of skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Range of motion of compromised joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying Women With Intermediate G6PD Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SD Biosensor STANDARD G6PD Test for Identifying Women With Intermediate G6PD Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Pain Intensity at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from range of Pressure Pain Thresholds at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-L1 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD-L1 expression positive rate (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anosognosia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin erythema responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: postoperative SNOT-22
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of oesophageal varix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Countermovement vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20 m sprints test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Hepatic Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With no Conversion of [13C] Cortisone to [13C] Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with major Adverse Kidney Events
Endpoint domain: Adverse events/effects
Primary endpoint: Energy Intake in Laboratory Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy Intake in Free-living Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Healing Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FMD in Response to Chronic HIIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in FMD in Response to Acute HIIT in the Untrained State
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in FMD in Response to Acute HIIT in the Trained State
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of adolescents receiving SBIRT protocol elements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of iodine deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maternal serum parameters of thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Psychomotor development at one year of age
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantity of Dystrophin Protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSAA Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participants Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Evaluated for Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious Adverse Drug Reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Survival Rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: HIV/STD incidence rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants That Need an Airway Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: International Standard Neurological Classification of Spinal Cord Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Re-rivascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Adolescent Depressive Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time of transition from orogastric to oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Sampling Time [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero Extrapolated to Infinity [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Revised Conflict Tactics Scale (CTS2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Relationship Satisfaction: Dyadic Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Multidimensional Measure of Emotional Abuse (MMEA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHOM scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CD34+ cell yields
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall global clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: maternal pre-eclampsia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: newborn's birthweight adjusted by gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infantil morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attachment behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patient's access to treatment and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: severe COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Major Pathological Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inventory of Interpersonal Problems-Circumplex version (IIP-C)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: changes in Platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in hemoglobin count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in absolute Neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total International Prostate Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with adequate zinc intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in partial oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in headache days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drugs intake per month
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hand-foot syndrome onset
Endpoint domain: Adverse events/effects
Primary endpoint: QoL C-30 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: regression of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma-equilibrated effect site concentration of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine albumin creatine ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Social avoidance and distress scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: dose distribution of GTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose distribution of CTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose distribution of PTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose distribution of heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dose distribution of ipsilateral lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dose distribution of bilateral breasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in adjustment and family functioning
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Outcomes from the Enhancing Connections Palliative Program as measured by the Child Behavior Check List
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in adjustment as measured by post-traumatic growth scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective response rate (ORR) for locoregional arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response rate (ORR) for metastatic arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects reporting at least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in levels of total B Cells in the peripheral blood circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal Oxygen Uptake (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of antibiotic resistant organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Experiencing a Serious Adverse Event (SAE) During the Study Therapy Period
Endpoint domain: Adverse events/effects
Primary endpoint: Median effective dose (ED50) of etomidate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS value (BIS50) of etomidate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of acute exacerbations (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of progressive-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change of B-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of liver enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 24hr Gastrointestinal and Colonic Transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knowledge of oral cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opinions about oral cancer screening competency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Current oral cancer screening practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in retinal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to Lower Respiratory Tract Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Treatment-emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Graft Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Distance covered during high-intensity intermittent exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute kidney injury prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lowering of plasma viral load after the first plasma infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of plasma viral load after a year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from 0MCM0107 baseline in Modified Cincinnati Rating System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS (Knee injury and Osteoarthritis Outcome Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients with clinically significant perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Dys-HDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mortality post treatment
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of time intragastric pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent change in fractional cholesterol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Response (CR and CRh) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 4-Month Relapse Free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Shoulder range of motion: flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder range of motion: abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder range of motion: extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder range of motion: rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P2Y12 Reaction Units at 4 Hours Post-Loading Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P2Y12 Reaction Units at 30 Days During Maintenance Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Infection related signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive Percent Agreement (PPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative Percent Agreement (NPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Angiographic in-stent late-loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted Post-test Score of Montreal Cognitive Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vascular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Alterations on Nasal septum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the alveolar cleft dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of vascugel
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events Related to Balsamic Bactrim
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Airway volume (iVaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Airway resistance (iRaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Low Attenuation or Emphysema Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum tolerated dose (MTD) of carfilzomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial response rate after 4 courses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates of carfilzomib, pomalidomide, dexamethasone, and daratumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Research Council (MRC) grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: proportion of patients with recurrent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: setup accuracy of conventional, invasive frame SRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing assessed on Vancouver Scar Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: willingness to verticalize
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: verticalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the first mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure Completed Without Change in Intra-abdominal Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Visualization Laparoscopic Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Estimation of steady-state oral clearance (Cl/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete expulsion of conceptus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Diagnosis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian Follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Decrease in the Visceral Fat Layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle Protein Synthesis or Fractional synthesis rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gamma-aminobutyric acid receptor A (GABA-A) potentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Default Mode Network (DMN) Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in tumor necrosis factor - alpha (TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Units Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: recurrent rate of tarlov cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Appropriate growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who experience specified events
Endpoint domain: Adverse events/effects